Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

First line of the email MUST contain the NCT# and Site #.


BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Back

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Recruiting

Open to: ALL

Age: 55.0 - 90.0

Aberdeen Motherwell Ilford Swinton London Chertsey Edinburgh Leeds Sheffield, SouthYorkshire Preston

Medical Conditions

Alzheimer Disease
Psychotic Disorders
Mental Disorders

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2023 Jul 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : KarXT 20/2 mg (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)

Intervention Arm Group : KarXT;

Intervention Type : DRUG
Intervention Description : Placebo Capsules

Intervention Arm Group : Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Local Institution - 2105
    Aberdeen
    AB25 2ZL
  • Local Institution - 2104
    Motherwell
    ML1 4UF
  • Local Institution - 2110
    Ilford
    Greater London
    IG1 4HP
  • Local Institution - 2108
    Swinton
    Greater Manchester
    M27 8FF
  • Local Institution - 2101
    London
    Surrey
    SE5 8AZ
  • Local Institution - 2109
    Chertsey
    KT16 9AU
  • Local Institution - 2112
    Edinburgh
    EH4 2XU
  • Local Institution - 2106
    Leeds
    LS7 3JX
  • Local Institution - 2107
    Sheffield, SouthYorkshire
    s5 7JT
  • Local Institution - 2111
    Preston
    PR2 9HT

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


First line of the email MUST contain the NCT# and Site #.



The study is sponsored by Karuna Therapeutics



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06126224
Last updated 03 March 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top